MSET — Mindset pharma Share Price
Last trade - 00:00- CA$74.96m
- CA$67.85m
- CA$3.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -78.82% | ||
Financial Summary
| Year End 30th Jun | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 3.91 | 11.4 | 21 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mindset Pharma Inc. is a Canada-based drug discovery and development company. The Company is engaged in the psychedelic-based drug discovery business focused on creating patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.
Directors
- Last Annual
- June 30th, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 12th, 2011
- Public Since
- July 21st, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 101,298,924
- Address
- 217 Queen Street West, Suite 401, TORONTO, M5V 0R2
- Web
- https://mindsetpharma.com/
- Phone
- +1 6479385266
- Auditors
- MNP LLP
Upcoming Events for MSET
Similar to MSET
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
As of Today at 24:14 UTC, shares in Mindset pharma are trading at CA$0.47. This share price information is delayed by 15 minutes.
Shares in Mindset pharma last closed at CA$0.47 and the price had moved by +42.42% over the past 365 days. In terms of relative price strength the Mindset pharma share price has outperformed the Toronto Stock Exchange 300 Composite Index by +31.48% over the past year.
The overall consensus recommendation for Mindset pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Mindset pharma does not currently pay a dividend.
Mindset pharma does not currently pay a dividend.
Mindset pharma does not currently pay a dividend.
To buy shares in Mindset pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.47, shares in Mindset pharma had a market capitalisation of CA$50.65m.
Here are the trading details for Mindset pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: MSET
Based on an overall assessment of its quality, value and momentum Mindset pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mindset pharma is CA$1.17. That is 150% above the last closing price of CA$0.47.
Analysts covering Mindset pharma currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.08 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mindset pharma. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +63.35%.
As of the last closing price of CA$0.47, shares in Mindset pharma were trading +33.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mindset pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mindset pharma's directors